Catheter ablation versus antiarrhythmic drugs with risk factor modification for treatment of atrial fibrillation: a protocol of a randomised controlled trial (PRAGUE-25 trial)

Pavel Osmancik, Štěpán Havránek, Veronika Bulková, Jan Chovančík, Tomáš Roubíček, Dalibor Heřman, Zuzana Čarná, Vladimír Tuka, Martin Matoulek, Martin Fiala, Otakar Jiravský, Sylvie Stregl-Hruskova, Adam Latiňák, Jiřina Kotryová, Jiří Jarkovský, Pavel Osmancik, Štěpán Havránek, Veronika Bulková, Jan Chovančík, Tomáš Roubíček, Dalibor Heřman, Zuzana Čarná, Vladimír Tuka, Martin Matoulek, Martin Fiala, Otakar Jiravský, Sylvie Stregl-Hruskova, Adam Latiňák, Jiřina Kotryová, Jiří Jarkovský

Abstract

Introduction: Atrial fibrillation (AF), with a prevalence of 2%, is the most common cardiac arrhythmia. Catheter ablation (CA) has been documented to be superior to treatment by antiarrhythmic drugs (AADs) in terms of sinus rhythm maintenance. However, in obese patients, substantial weight loss was also associated with AF reduction. So far, no study has compared the modern non-invasive (AADs combined with risk factor modification (RFM)) approach with modern invasive (CA) treatment. The aim of the trial is to compare the efficacy of modern invasive (CA) and non-invasive (AADs with risk factor management) treatment of AF.

Methods and analysis: The trial will be a prospective, multicentre, randomised non-inferiority trial. Patients with symptomatic AF and a body mass index >30 will be enrolled and randomised to the CA or RFM arm (RFM+AAD) in a 1:1 ratio. In the CA arm, pulmonary vein isolation (in combination with additional lesion sets in non-paroxysmal patients) will be performed. For patients in the RFM+AAD arm, the aim will be a 10% weight loss over 6-12 months, increased physical fitness and a reduction in alcohol consumption. The primary endpoint will be an episode of AF or regular atrial tachycardia lasting >30 s. The secondary endpoints include AF burden, clinical endpoints associated with AF reoccurrence, changes in the quality of life assessed using dedicated questionnaires, changes in cardiorespiratory fitness and metabolic endpoints. An AF freedom of 65% in the RFM+AAD and of 60% in the CA is expected; therefore, 202 patients will be enrolled to achieve the non-inferiority with 80% power, 5% one-sided alpha and a non-inferiority margin of 12%.

Ethics and dissemination: The PRAGUE-25 trial will determine if modern non-invasive AF treatment strategies are non-inferior to CA. The study was approved by the Ethics Committee of the University Hospital Kralovske Vinohrady. Results of the study will be disseminated on scientific conferences and in peer-reviewed scientific journals. After the end of follow-up, data will be available upon request to principal investigator.

Trial registration number: ClinicalTrials.gov Registry (NCT04011800).

Keywords: Adult cardiology; NUTRITION & DIETETICS; Pacing & electrophysiology.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
CONSORT diagram of the study. AF, atrial fibrillation; BMI, body mass index; CONSORT, Consolidated Standards of Reporting Trials; QoL, quality of life.

References

    1. Lloyd-Jones DM, Wang TJ, Leip EP, et al. . Lifetime risk for development of atrial fibrillation: the Framingham heart study. Circulation 2004;110:1042–6. 10.1161/01.CIR.0000140263.20897.42
    1. Chugh SS, Havmoeller R, Narayanan K, et al. . Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation 2014;129:837–47. 10.1161/CIRCULATIONAHA.113.005119
    1. Piccini JP, Lopes RD, Kong MH, et al. . Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials. Circ Arrhythm Electrophysiol 2009;2:626–33. 10.1161/CIRCEP.109.856633
    1. Marrouche NF, Brachmann J, Andresen D, et al. . Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:417–27. 10.1056/NEJMoa1707855
    1. Packer DL, Mark DB, Robb RA, et al. . Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA 2019;321:1261–74. 10.1001/jama.2019.0693
    1. Wazni OM, Dandamudi G, Sood N, et al. . Cryoballoon ablation as initial therapy for atrial fibrillation. N Engl J Med 2021;384:316–24. 10.1056/NEJMoa2029554
    1. Andrade JG, Wells GA, Deyell MW, et al. . Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med 2021;384:305–15. 10.1056/NEJMoa2029980
    1. Lafuente-Lafuente C, Valembois L, Bergmann J-F, et al. . Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2015:CD005049. 10.1002/14651858.CD005049.pub4
    1. Kirchhof P, Camm AJ, Goette A, et al. . Early Rhythm-Control therapy in patients with atrial fibrillation. N Engl J Med 2020;383:1305–16. 10.1056/NEJMoa2019422
    1. Freemantle N, Lafuente-Lafuente C, Mitchell S, et al. . Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace 2011;13:329–45. 10.1093/europace/euq450
    1. Goldschlager N, Epstein AE, Naccarelli GV, et al. . A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm 2007;4:1250–9. 10.1016/j.hrthm.2007.07.020
    1. Lavie CJ, Pandey A, Lau DH, et al. . Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis: effects of weight loss and exercise. J Am Coll Cardiol 2017;70:2022–35. 10.1016/j.jacc.2017.09.002
    1. Middeldorp ME, Pathak RK, Meredith M, et al. . Prevention and regressive effect of weight-loss and risk factor modification on atrial fibrillation: the REVERSE-AF study. Europace 2018;20:1929–35. 10.1093/europace/euy117
    1. Wong CX, Sullivan T, Sun MT, et al. . Obesity and the Risk of Incident, Post-Operative, and Post-Ablation Atrial Fibrillation: A Meta-Analysis of 626,603 Individuals in 51 Studies. JACC Clin Electrophysiol 2015;1:139–52. 10.1016/j.jacep.2015.04.004
    1. Conen D, Tedrow UB, Koplan BA, et al. . Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation 2009;119:2146–52. 10.1161/CIRCULATIONAHA.108.830042
    1. Gami AS, Hodge DO, Herges RM, et al. . Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 2007;49:565–71. 10.1016/j.jacc.2006.08.060
    1. Kodama S, Saito K, Tanaka S, et al. . Alcohol consumption and risk of atrial fibrillation: a meta-analysis. J Am Coll Cardiol 2011;57:427–36. 10.1016/j.jacc.2010.08.641
    1. Pathak RK, Middeldorp ME, Lau DH, et al. . Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol 2014;64:2222–31. 10.1016/j.jacc.2014.09.028
    1. Pathak RK, Middeldorp ME, Meredith M, et al. . Long-Term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (legacy). J Am Coll Cardiol 2015;65:2159–69. 10.1016/j.jacc.2015.03.002
    1. Malmo V, Nes BM, Amundsen BH, et al. . Aerobic interval training reduces the burden of atrial fibrillation in the short term: a randomized trial. Circulation 2016;133:466–73. 10.1161/CIRCULATIONAHA.115.018220
    1. Voskoboinik A, Kalman JM, De Silva A, et al. . Alcohol abstinence in drinkers with atrial fibrillation. N Engl J Med 2020;382:20–8. 10.1056/NEJMoa1817591
    1. Al Chekakie MO, Welles CC, Metoyer R, et al. . Pericardial fat is independently associated with human atrial fibrillation. J Am Coll Cardiol 2010;56:784–8. 10.1016/j.jacc.2010.03.071
    1. Mirolo A, Viart G, Savouré A, et al. . Epicardial fat thickness predicts atrial fibrillation recurrence after a first pulmonary vein isolation procedure using a second-generation cryoballoon. Arch Cardiovasc Dis 2019;112:314–22. 10.1016/j.acvd.2018.11.011
    1. Ling L-H, Kistler PM, Ellims AH, et al. . Diffuse ventricular fibrosis in atrial fibrillation: noninvasive evaluation and relationships with aging and systolic dysfunction. J Am Coll Cardiol 2012;60:2402–8. 10.1016/j.jacc.2012.07.065
    1. McLellan AJA, Ling L-han, Azzopardi S, et al. . Diffuse ventricular fibrosis measured by T₁ mapping on cardiac MRI predicts success of catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol 2014;7:834–40. 10.1161/CIRCEP.114.001479
    1. Eschalier R, Rossignol P, Kearney-Schwartz A, et al. . Features of cardiac remodeling, associated with blood pressure and fibrosis biomarkers, are frequent in subjects with abdominal obesity. Hypertension 2014;63:740–6. 10.1161/HYPERTENSIONAHA.113.02419
    1. Bianchi VE. Weight loss is a critical factor to reduce inflammation. Clin Nutr ESPEN 2018;28:21–35. 10.1016/j.clnesp.2018.08.007
    1. Jiang H, Wang W, Wang C, et al. . Association of pre-ablation level of potential blood markers with atrial fibrillation recurrence after catheter ablation: a meta-analysis. Europace 2017;19:392–400. 10.1093/europace/euw088
    1. Sasaki N, Okumura Y, Watanabe I, et al. . Increased levels of inflammatory and extracellular matrix turnover biomarkers persist despite reverse atrial structural remodeling during the first year after atrial fibrillation ablation. J Interv Card Electrophysiol 2014;39:241–9. 10.1007/s10840-013-9867-6
    1. Bin Waleed K, Yin X, Yang X, et al. . Short and long-term changes in platelet and inflammatory biomarkers after cryoballoon and radiofrequency ablation. Int J Cardiol 2019;285:128–32. 10.1016/j.ijcard.2019.02.054
    1. Pelliccia A, Sharma S, Gati S, et al. . 2020 ESC guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 2021;42:17–96. 10.1093/eurheartj/ehaa605
    1. Calkins H, Reynolds MR, Spector P, et al. . Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol 2009;2:349–61. 10.1161/CIRCEP.108.824789
    1. Poole JE, Bahnson TD, Monahan KH, et al. . Recurrence of Atrial Fibrillation After Catheter Ablation or Antiarrhythmic Drug Therapy in the CABANA Trial. J Am Coll Cardiol 2020;75:3105–18. 10.1016/j.jacc.2020.04.065

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa